10:10 AM EST, 11/05/2025 (MT Newswires) -- Charles River Laboratories International ( CRL ) said Wednesday it plans to sell certain underperforming or non-core businesses representing around 7% of the company's estimated 2025 revenue as part of efforts to streamline operations.

The proposed divestitures are expected to result in non-GAAP earnings per share accretion of at least $0.30 on an annualized basis, before any reinvestment of the proceeds, Charles River said.

The company also said it expects its restructuring initiatives over the past years to generate about $225 million in cumulative, annualized cost savings in 2026, and its efforts to achieve greater operating efficiencies to result in incremental net cost savings of about $70 million annually, to be fully realized in 2026.

Additionally, the company said its board has approved a $1 billion stock repurchase authorization, replacing the previous stock buyback program under which it had repurchased $450.7 million in common stock since August 2024.

Shares of Charles River were down more than 8% in recent trading Wednesday.

Price: 162.80, Change: -15.09, Percent Change: -8.48